MedTrace Logo

A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

NCT00786058 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2009-06-15

No results posted yet for this study

Summary

The purpose of this study is to compare best supportive care plus oxaliplatin/ folinic acid/ 5-FU versus best supportive alone in patients with gemcitabine refractory pancreatic cancer.

Conditions

Interventions

DRUG

OFF in experimental arm

OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • medac GmbH

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • CONKO-Studiengruppe

    lead OTHER

Principal Investigators

  • Helmut Oettle, PD · CONKO Study Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00786058 on ClinicalTrials.gov